Heijerman, Harry G M <br/><br/>
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.  [electronic resource] 

 -  Lancet (London, England)  11 2019 
 - 1940-1948 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(19)32597-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Aminophenols--administration & dosage<br/>Benzodioxoles--administration & dosage<br/>Child<br/>Chloride Channel Agonists--administration & dosage<br/>Cystic Fibrosis--drug therapy<br/>Cystic Fibrosis Transmembrane Conductance Regulator--genetics<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Male<br/>Pyrazoles--administration & dosage<br/>Pyridines--administration & dosage<br/>Pyrrolidines--administration & dosage<br/>Quinolones--administration & dosage<br/>Sweat--chemistry